Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 2.
Have previously untreated and histological examination confirms resectable stage II-IIIA/IIIB non-small cell lung cancer (according to the 8th edition of the AJCC TNM staging criteria), and the pathological type of squamous cell carcinoma and non-squamous cell carcinoma needs to be distinguished, and EGFR, ALK, and ROS1 should be negative for non-squamous non-small cell lung cancer
Adequate organ function and expected survival time ≥ 12 weeks;
Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients.
You may not be if
Presence of mixed carcinoma component on histology.
Patients with other active malignancies within 5 years prior to enrollment.
Known active autoimmune diseases.
Currently participate in an interventional clinical study treatment or have been treated with another drug or investigational device within 4 weeks prior to the first dose.
Use of immunosuppressive agents within 14 days prior to the first dose of study treatment.
Presence of other uncontrolled serious medical conditions.
